Overexpression and clinical significance of IBP in epithelial ovarian carcinoma

  • Authors:
    • Yingjuan Xu
    • Yangming Hou
    • Tianbo Liu
    • Ge Lou
  • View Affiliations

  • Published online on: February 27, 2018     https://doi.org/10.3892/ol.2018.8125
  • Pages: 6604-6610
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Interferon regulatory factor‑4 binding protein (IBP) is as a type of ρ GTPase suggested to serve an important role in tumor occurrence and development through the effects of cytoskeletal remodeling, and cell conduction mechanism. IBP is widely expressed in the immune system and expressed in several types of tumors. However, its expression and prognostic value in epithelial ovarian carcinoma (EOC) remain unclear. The present study aimed to investigate the expression of IBP in EOC, and its effect on clinicopathological variables and prognosis. A total of 107 and 30 cases of epithelial ovarian carcinoma and benign ovarian disease tissue sections, respectively, were examined using immunohistochemistry. The results indicated that the IBP expression status was negative or markedly weak in normal tissues, but highly expressed in EOC tissues. A significant association was observed between IBP overexpression and various clinicopathological factors, including advanced International Federation of Gynecology and Obstetrics stage (P<0.001), poor histologic grade (P=0.002), peritoneal carcinomatosis (P<0.001), lymph‑node metastasis (P=0.023) and recurrence (P<0.001). Multivariate Cox regression analysis additionally suggested that IBP overexpression was an independent factor affecting recurrence‑free survival [hazard ratio (HR)=4.099; 95% confidence interval (CI), 2.209‑7.606; P<0.001) and overall survival (HR=2.317; 95% CI, 1.484‑3.617; P<0.001) in patients with EOC. The results of the present study demonstrated that IBP overexpression may be associated with tumor development and progression in EOC, and therefore may serve as a novel target for treating this disease.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu Y, Hou Y, Liu T and Lou G: Overexpression and clinical significance of IBP in epithelial ovarian carcinoma. Oncol Lett 15: 6604-6610, 2018
APA
Xu, Y., Hou, Y., Liu, T., & Lou, G. (2018). Overexpression and clinical significance of IBP in epithelial ovarian carcinoma. Oncology Letters, 15, 6604-6610. https://doi.org/10.3892/ol.2018.8125
MLA
Xu, Y., Hou, Y., Liu, T., Lou, G."Overexpression and clinical significance of IBP in epithelial ovarian carcinoma". Oncology Letters 15.5 (2018): 6604-6610.
Chicago
Xu, Y., Hou, Y., Liu, T., Lou, G."Overexpression and clinical significance of IBP in epithelial ovarian carcinoma". Oncology Letters 15, no. 5 (2018): 6604-6610. https://doi.org/10.3892/ol.2018.8125